Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.
about
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmissionPrimaquine or other 8-aminoquinoline for reducing P. falciparum transmissionThe role of early detection and treatment in malaria eliminationTools and Strategies for Malaria Control and Elimination: What Do We Need to Achieve a Grand Convergence in Malaria?Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationG6PD deficiency: a classic example of pharmacogenetics with on-going clinical implicationsReview of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop reportSustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytesSingle Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient SubjectsSafety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies.Glucose-6-phosphate dehydrogenase deficiency in people living in malaria endemic districts of NepalSingle dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.Glucose-6-phosphate dehydrogenase deficiency A- variant in febrile patients in Haiti.Malaria: an update on current chemotherapy.Primaquine: the risks and the benefitsOpen-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Field trial evaluation of the performances of point-of-care tests for screening G6PD deficiency in Cambodia.Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations.Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malariaThe gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trialMass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.Evaluation of the diagnostic accuracy of CareStart G6PD deficiency Rapid Diagnostic Test (RDT) in a malaria endemic area in Ghana, Africa.Population-wide malaria testing and treatment with rapid diagnostic tests and artemether-lumefantrine in southern Zambia: a community randomized step-wedge control trial design.An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa.Prevalence and Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency at the China-Myanmar BorderTolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiencySubmicroscopic carriage of Plasmodium falciparum and Plasmodium vivax in a low endemic area in Ethiopia where no parasitaemia was detected by microscopy or rapid diagnostic test.Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in CambodiaIn Vitro Activities of Primaquine-Schizonticide Combinations on Asexual Blood Stages and Gametocytes of Plasmodium falciparumModelling the therapeutic dose range of single low dose primaquine to reduce malaria transmission through age-based dosing.Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda.Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in TanzaniaDevelopment of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.Prevalence of G6PD deficiency and Plasmodium falciparum parasites in asymptomatic school children living in southern Ghana.Spatial distribution of G6PD deficiency variants across malaria-endemic regions.Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China.Cytostatic versus cytocidal profiling of quinoline drug combinations via modified fixed-ratio isobologram analysis.Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
P2860
Q24188070-93353F2D-9AAB-4423-8B66-DFE6A15C357AQ24193716-F05642D5-3CB4-4875-99D2-D64E5A8E038DQ26740068-20FCEC0E-151C-4904-A9A6-F2817E08F280Q26765029-6F8A5C3A-8956-4868-9E31-1EA82D358E36Q26830528-B7CDB7A9-14FC-4E02-882C-51FAF53A440CQ27005605-82660FBB-036D-463E-A103-4D93234F1A0DQ27024922-210EE3AD-2BFE-4870-9640-C46D8A53C8D8Q28125936-93FC17DD-B4F9-4843-8CF8-346CC1097B34Q28550990-F5B17A55-9949-41EB-A875-F3649865D191Q33626090-C1F3A69E-0D50-4A33-B388-08282C728BC4Q33721887-220B5DFE-5253-4EDE-94B7-87DEFA37B430Q33772980-224DFAE4-8FF0-4DBF-8C16-0B41232C8A1EQ34016023-717B28A6-9FDB-4687-8264-BBE405E54ABEQ34433106-2298BBAF-BD13-4A12-A18E-E61FFADBF4ACQ34503631-4B97B28F-66FA-48C9-995F-124368874260Q34597891-961298B4-0C89-40F2-B138-603C6EBC75E4Q34777088-AC3D98DF-3DDC-471D-9B61-F40774227CD5Q34922792-8974504E-3D67-40BC-8A32-BF24E1EB243AQ34968407-D4030B78-1C2F-4475-9BFA-E52568FBA6E1Q35147721-EFB3616A-12A8-4F7E-BDF1-E931B2D381ACQ35224221-97193E7C-A129-4037-BBFB-13222EB08212Q35464096-3329D383-7344-4E73-8042-253E5CCFBBF5Q35590734-057F3084-9430-453C-A2ED-7400A5DC9790Q35655782-641231C0-EAD6-46CE-B073-E9388FA7EF6FQ35727140-42D7798E-4106-40DF-A354-2E1EEBB901AEQ35754020-8C6AEB1A-A34E-44A7-A266-AFE7DC3A4996Q35913794-C6F9C8DF-69E6-42AD-A041-F8144D0848ECQ35948587-15F99F71-E9FB-44F1-AD89-3DD2941A3953Q36175374-5414C37F-6B27-4328-931A-C9E589786EABQ36290632-871F3D0C-EABB-4FF6-B7F9-82F1E89DB936Q36340896-4B5E0057-314E-4EAE-9B32-F4865D1C34DCQ36730218-887B402B-9435-4655-9A01-5219C9CDA025Q36969682-2C1FF82D-593E-491F-B575-7860BE463F1EQ36991071-1E2DD8FB-C798-488E-9DED-019312429BE6Q37119572-BF1CB35F-6AA3-4F9F-AE8E-45CEFB9EB052Q37125793-C2AAD1B5-3464-48F5-9A01-102EA89B848DQ37329332-3B5A43FD-D5C8-48BB-AA1B-5B6123240E99Q37348028-865F3B19-9460-44DC-85A3-32820F10B47DQ37418342-8CFD091E-D496-4C9A-BAAF-F3A6491456C6Q37480757-2EEDF06E-F3C0-49D3-9501-3597F3B53ACA
P2860
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rationale for recommending a l ...... ere G6PD deficiency is common.
@ast
Rationale for recommending a l ...... ere G6PD deficiency is common.
@en
type
label
Rationale for recommending a l ...... ere G6PD deficiency is common.
@ast
Rationale for recommending a l ...... ere G6PD deficiency is common.
@en
prefLabel
Rationale for recommending a l ...... ere G6PD deficiency is common.
@ast
Rationale for recommending a l ...... ere G6PD deficiency is common.
@en
P2860
P921
P356
P1433
P1476
Rationale for recommending a l ...... ere G6PD deficiency is common.
@en
P2093
P2860
P2888
P356
10.1186/1475-2875-11-418
P5008
P577
2012-12-14T00:00:00Z
P5875
P6179
1017392148